The Revised French-American-British Classification of Acute Myeloid Leukemia: Is New Better?

1985 ◽  
Vol 103 (4) ◽  
pp. 614 ◽  
Author(s):  
CLARA D. BLOOMFIELD
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
French American British ◽  
Acute Myeloid

Acute Leukemia

2016 ◽  
Author(s):  
Richard A. Larson ◽  
Roland B Walter
Keyword(s):  
Acute Myeloid Leukemia ◽  
Acute Lymphoblastic Leukemia ◽  
Acute Leukemia ◽  
Myeloid Leukemia ◽  
Who Classification ◽  
Lymphoblastic Leukemia ◽  
World Health ◽  
Acute Leukemias ◽  
Acute Myeloid

The acute leukemias are malignant clonal disorders characterized by aberrant differentiation and proliferation of transformed hematopoietic progenitor cells. These cells accumulate within the bone marrow and lead to suppression of the production of normal blood cells, with resulting symptoms from varying degrees of anemia, neutropenia, and thrombocytopenia or from infiltration into tissues. They are currently classified by their presumed cell of origin, although the field is moving rapidly to genetic subclassification. This review covers epidemiology; etiology; classification of leukemia by morphology, immunophenotyping, and cytogenetic/molecular abnormalities; cytogenetics of acute leukemia; general principles of therapy; acute myeloid leukemia; acute lymphoblastic leukemia; and future possibilities. The figure shows the incidence of acute leukemias in the United States. Tables list World Health Organization (WHO) classification of acute myeloid leukemia and related neoplasms, expression of cell surface and cytoplasmic markers for the diagnosis of acute myeloid leukemia and mixed-phenotype acute leukemia, WHO classification of acute lymphoblastic leukemia, WHO classification of acute leukemias of ambiguous lineage, WHO classification of myelodysplastic syndromes, European LeukemiaNet cytogenetic and molecular genetic subsets in acute myeloid leukemia with prognostic importance, cytogenetic and molecular subtypes of acute lymphoblastic leukemia, terminology used in leukemia treatment, and treatment outcome for adults with acute leukemia. This review contains 1 highly rendered figure, 9 tables, and 117 references.

Impact of 9q deletions on the classification of patients with acute myeloid leukemia

2019 ◽  
Vol 145 (11) ◽  
pp. 2871-2874
Author(s):  
Bettina Balk ◽  
Torsten Haferlach ◽  
Manja Meggendorfer ◽  
Wolfgang Kern ◽  
Claudia Haferlach ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Acute Myeloid

scholarly journals PF197 A NEW CLASSIFICATION OF ACUTE MYELOID LEUKEMIA BASED ON INTEGRATED GENOMICS AND METABOLOMICS

HemaSphere ◽  
2019 ◽  
Vol 3 (S1) ◽  
pp. 51
Author(s):  
G. Simonetti ◽  
A. Padella ◽  
C. Mengucci ◽  
E. Fonzi ◽  
G. Picone ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
New Classification ◽  
Integrated Genomics ◽  
Acute Myeloid

Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia.

1993 ◽  
Vol 11 (4) ◽  
pp. 690-697 ◽  
Author(s):  
M S Tallman ◽  
D Hakimian ◽  
J M Shaw ◽  
G S Lissner ◽  
E J Russell ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
World Literature ◽  
Granulocytic Sarcoma ◽  
Signs And Symptoms ◽  
Free Survival ◽  
A Cell ◽  
Karyotype Analyses ◽  
French American British ◽  
Acute Myeloid

PURPOSE Since the only three cases of granulocytic sarcoma among patients with acute myeloid leukemia (AML) seen at our institution during the last 12 years were each associated with the 8;21 translocation [t(8;21)], we sought to determine if this association is specific and more frequent than previously recognized. PATIENTS AND METHODS We report three patients with AML and t(8;21) who developed granulocytic sarcomas, and review the world literature. RESULTS Between 1980 and 1992, 53 cases of AML French-American-British (FAB) M2 were identified at our institution. Eight (15%) patients had t(8;21). Three of these eight patients (38%) developed granulocytic sarcoma. All three of our patients received conventional intensive antileukemic chemotherapy yet had short relapse-free survival durations. Several series of patients with t(8;21) report that granulocytic sarcomas occur in approximately 18% of this population, which is four times the expected incidence in AML. Thirty-seven cases have been previously reported. Although karyotype analyses were not reported in many cases of granulocytic sarcoma in the literature, the vast majority of abnormal karyotypes in patients with AML involved t(8;21). Recent work with a cell line derived from a patient with t(8;21) indicates that such cells are unusually adherent to culture bottles and are aggregable CONCLUSION Our data suggest that this association is more common than generally recognized and may be specific. Patients with t(8;21) should be observed closely for signs and symptoms of granulocytic sarcoma. These patients may have a less favorable prognosis than other patients with t(8;21). Cooperative oncology groups should retrospectively identify patients with AML and t(8;21) who had a poor outcome to determine if they had a disproportionate incidence of granulocytic sarcoma. If so, aggressive therapy such as bone marrow transplantation may be warranted early in the therapeutic strategy.

Usefulness and limitations of serum and urine lysozyme levels in the classification of acute myeloid leukemia: An analysis of 208 cases

1996 ◽  
Vol 20 (6) ◽  
pp. 467-472 ◽  
Author(s):  
Carol Sexton ◽  
David Buss ◽  
Bayard Powell ◽  
Michael O'Connor ◽  
Robert Rainer ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Acute Myeloid ◽  
Serum And Urine

scholarly journals c-fms expression is a molecular marker of human acute myeloid leukemias

Blood ◽  
1988 ◽  
Vol 72 (3) ◽  
pp. 1081-1085 ◽  
Author(s):  
P Dubreuil ◽  
H Torres ◽  
MA Courcoul ◽  
F Birg ◽  
P Mannoni
Keyword(s):  
Acute Myeloid Leukemia ◽  
Molecular Marker ◽  
Myeloid Leukemia ◽  
Northern Blot Analysis ◽  
Leukemic Cells ◽  
Myeloid Leukemias ◽  
Fab Classification ◽  
Polypeptide Growth Factor ◽  
French American British ◽  
Acute Myeloid

The c-fms protooncogene product was identified as the CSF-1 or M-CSF receptor, a polypeptide growth factor that plays a major role in myelomonocytic differentiation. This led us to look for expression of c- fms in fresh acute myeloid leukemia (AML) cells, using Northern blot analysis. c-fms expression was found in the leukemic cells of 28 AML patients, regardless of their stage of differentiation, which was assessed in the French-American-British (FAB) classification. However, the level of c-fms expression was especially high in AML of the M5 stage. High levels of expression were not accompanied by either amplification or rearrangements of the c-fms gene in AML cell DNAs. In contrast, c-fms expression was not found in acute lymphoid leukemias, whether of T or B origin. Thus, c-fms expression appears as a specific molecular marker of leukemogenesis in the myeloid lineage.

Sign in / Sign up

Export Citation Format

Share Document